Jpmorgan Chase & CO Zymeworks Inc. Transaction History

Jpmorgan Chase & CO

  • $1.22 Trillion
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 11, 2022
SELL
$4.82 - $7.7 $3.31 Million - $5.29 Million
-686,773 Reduced 100.0%
11 $0
Q1 2022

May 11, 2022
BUY
$6.0 - $16.98 $3.67 Million - $10.4 Million
610,892 Added 804.95%
686,784 $4.5 Million
Q4 2021

Feb 10, 2022
BUY
$15.19 - $29.33 $682,228 - $1.32 Million
44,913 Added 144.98%
75,892 $1.25 Million
Q3 2021

Nov 12, 2021
BUY
$27.35 - $37.28 $847,275 - $1.15 Million
30,979 New
30,979 $900,000

Others Institutions Holding ZYME

# of Institutions
1
Shares Held
296K
Call Options Held
0
Put Options Held
0
View Full List

About Zymeworks Inc.

ZYME Quotes by TradingView
  • Ticker ZYME
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 61,694,400
  • Market Cap $901M
  • Description
  • Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas...
More about ZYME
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email